Human mesenchymal stem cells (hMSCs) are multipotent adult stem cells present in a variety of tissue niches within the human body. As multipotent cells, they can differentiate into a range of cell types, including osteoblasts, chondrocytes, myocytes, and adipocytes. In addition to secreting factors that can stimulate tissue repair, MSCs can substantially alter their microenvironment, exerting effects that are both anti-inflammatory and anti-fibrotic. [Read more…]
Cytonome cell sorter aids in Parkinson’s treatment
April 6, 2021, BEDFORD, Mass. — Cell sorting technology leader and innovator Cytonome-ST, LLC, has assisted pharmaceutical firm Sumitomo Dainippon Pharma Co., Ltd. to produce enough human stem cells to proceed with a clinical trial of a new treatment aimed at curing Parkinson’s Disease. [Read more…]
Global Market for iPSCs by Biomedical Application
Globally, companies have deployed an impressive range of business models for exploiting iPSC technology platforms. To date, iPSCs have found applications within academic research, drug discovery, toxicology testing, cell therapy, personalized medicine, disease modelling, industrial-scale manufacturing, biobanking, clean-meat production, and beyond. [Read more…]
How Human iPSCs are Revolutionizing Drug Discovery in 2021
Drug discovery involves high cost and uncertain outcomes. Only a few companies can take the risk of investing enormous amounts of money into research and testing, only to see undesirable side effects emerge during the final human clinical trials. In many cases, companies are spending millions of dollars to fail during clinical testing.
Now, some new medicines are being tested for safety on specialized cells developed from human pluripotent cell lines. Cells types which are frequently being using within drug discovery applications include heart (cardiomyocytes) and liver cells (hepatocytes), which are the organs where 80% of drug failures occur. [Read more…]
Century Therapeutics Raises $160M for iPSC-derived CAR-T and CAR-NK Cell Therapeutics
In early March, Century Therapeutics made waves by raising $160 million in Series C financing. This was on top of the existing $250 million that the company raised during a Series A round in 2019, bringing its total financing to an astounding $410 million. The Series C financing round was led by Casdin Capital, a New York-based investment firm that targets life science and healthcare companies. [Read more…]